Positive data from VBL Therapeutics' VB-201 Phase 2 study on psoriasis ... - News-Medical.net

Positive data from VBL Therapeutics' VB-201 state of matter 2 study on disease of the skin ... News-Medical.net VBL Therapeutics, a clinical stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that a Phase 2 sub-study of VB-201 in average to severe psoriasis patients with ... VBL medical specialty Presents Positive Phase ii Data for VB-201 in Psoriasis and ... MarketWatch (press release) all ii news articles » Link To Article